Patient’s Corner: Living with Chronic Illness Vol. 2

By Dorothy Leone-Glasser

I met Mapillar Dahn and the MTS Sickle Cell Foundation, Inc. at our Rx in Reach GA Coalition Capitol Day. She was excited to participate in our event and had a table set to distribute Sickle Cell Awareness material and to engage visitors, attendees and legislators on the challenges of living with and caring for patients with this illness. She is guiding others to participate in understanding and conquering Sickle Cell Disease. I wanted you to know Mapillar and her journey as she continues her crusade to dispel the myths and ignorance surrounding the devasting sickle cell disease. 

Mapillar Dahn founded MTS Sickle Cell Foundation, Inc., a non-profit organization, to bring awareness to sickle cell disease and provide support to families affected by Sickle Cell Disease (SCD). Since its inception in November of 2015, the foundation has implemented many initiatives to assist sickle cell families giving them a community of healing and hope. MTS Foundation has sponsored over 100 children attending week-long summer camp, organizing health fairs, helping families avoid eviction and disconnection of vital utilities while conducting outreach visits to hospitalized sickle cell patients. The MTS Foundation works to spread sickle cell awareness and support clinical trials reaching over 20 million people in the United States and Canada.

SCD is an incredibly complex genetic blood disorder that impacts 100,000 Americans and millions more around the world. Because it is a blood disease, it’s complications can be felt anywhere blood flows in the body. A person can go blind from it, have a stroke, have organ damage, experience excruciatingly painful episodes called crises, and even die from its complications. Sickle Cell is an invisible disease that many outside of the SCD community, simply do not understand. This misunderstanding and a general lack of education around SCD has caused many myths and misconceptions about the disease to fester and cause systemically toxic and stigmatizing beliefs.

Mapillar Dhan is personally inspired to fight for those affected by sickle cell because she is the mother of three (3) beautiful daughters who all battle Sickle Cell Disease. She knows firsthand what people don’t know about living with this challenging disease and caring for children who struggle with its symptoms daily.  She is compelled to speak out loud and share a few points to keep in mind when engaging with SCD patients. She believes; the more you know, the more you can crush the barriers to care so patients can be assured they will receive the timely and appropriate treatment that they deserve. 

Here are some of her ‘Tips”:

  • RESPECT THE EXPERTISE OF THE PATIENT:  More needs to be done to build communication, sensitivity and awareness with SCD patients. Patients are experts in their own disease. SCD patients are not seen as partners in their own care. If a patient says, “This drug doesn’t work for me, but that one does,” what the doctor hears is, “This person has a drug of choice”. What is true is the SCD patient has lived with their disease since birth and knows what works for them.
  • SICK PEOPLE DO NOT ALWAYS LOOK SICK:  Please do not tell a SCD patient that he or she does not look sick. It is incredibly offensive and very hurtful. This is a community that has real issues with being taken seriously, especially in the hospital setting. SCD patients all around this country are being made to feel like they are faking their pain by medical professionals. They are being told that they are drug seekers simply because you can’t see their pain. SCD impacts every aspect of a person’s life and is extremely debilitating. Even when you do not see the severity of their illness; that does not mean that they are not experiencing a great deal of pain or feel very sick.
  • IT’S OK TO SAY YOU DON’T KNOW:  I wish more medical professionals would say that they do not know about how to treat SCD patients instead of minimizing their pain, rushing their care, and prematurely sending them home, only for them to return to the hospital oftentimes in an even much critical condition than before. When it comes to treating SCD complications, time does matter
  • THE DISEASE AFFECTS EVERYONE DIFFERENTLY:  
    My daughters are three sisters with the same mother and father all battling the same disease. They all have different symptoms and different experiences.

My oldest daughter, Tully, who is now 17, started to have severe bouts of pain, known as pain crises, when she was 6 months old. Until a year ago, she was having two to three crises a year, which means she was hospitalized for at least a week. About a year ago, after a blood transfusion, she developed antibodies to the blood group antigen, Jsb, which means she can only get transfusions from the 1-2% of donors who lack this antigen.
My other daughters have not had pain crises, but my middle daughter, Khadeejah, who is 15, had a stroke when she was 7 years old. Since then, she’s had monthly blood transfusions and 10 surgeries, including a major brain surgery.
My youngest daughter, Hajar, who is 11, struggles with the disease in her own way. She doesn’t have obvious symptoms or require regular blood transfusions, but she has cognitive challenges that are the result of “silent” mini-strokes associated with SCD.

“We have to look at individual patients and treat the disease more broadly. As a community, we know that not much is taught about sickle cell disease in medical and nursing schools. Until we can work to change that, a healthy dose of vulnerability, understanding, compassion, care, and empathy needs to be prescribed when treating people with SCD.”

To learn more about MTS Sickle Cell Foundation click  here.

Mapillar Dahn headshot
Mapillar Dahn
Founder & CEO,
MTS Sickle Cell Foundation
Dorothy Leone Glasser headshot
Dorothy Leon Glasser
Executive Director, Advocates for Responsible Care
Co-Chair, Georgia Bio Patient Advocacy Alliance
September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.
September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
August 31, 2026
The White House, August 31, 2026 - ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). The agreements bring the total number of pharmaceutical manufacturers with MFN deals to 26, covering 89% of the branded drug market. The nine manufacturers are comprised of mid-sized pharmaceutical companies, including Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements reduce prices on drugs that treat numerous costly, chronic, and even rare diseases, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer. The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable. The agreements ensure foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market. Each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients. BOLSTERING AMERICA’S PHARMACEUTICAL SUPPLY CHAINS AND RESERVES: These nine pharmaceutical manufacturers committed to invest at least $19.6 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the MFN agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency. UCB will contribute 163 tons of levetiracetam, an anticonvulsant used to control and prevent certain types of seizures, to the SAPIR. Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline; both antibiotics to treat bacterial infections, to the SAPIR. Teva Pharmaceuticals will contribute 45 metric tons of metronidazole, an antibiotic and antiprotozoal used to treat certain bacterial and parasitic infections, and 4.8 tons of amlodipine, an antihypertensive drug, to the SAPIR. Astellas will contribute 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have had organ transplants, to the SAPIR. LOWERING COSTS FOR AMERICANS: President Trump’s decisive and historic actions are lowering drug prices for the American people. Since its February launch, patients have saved more than $700 million on medicines through TrumpRx, including massive discounts on some of the most popular and costly medications used to treat obesity and infertility. In July of 2026, senior citizens without access to GLP-1 coverage to treat obesity gained access for just $50 per month. In the two months since the launch of this program, over 500,000 seniors have saved a total of $216 million dollars on these life-changing medicines. The Council of Economic Advisers estimates the total savings from President Trump’s MFN deals to reach $600 billion over the next decade. DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients, accomplishing historic wins that the political establishment did not believe were possible. On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations. On July 31, 2025, President Trump sent letters to 17 of the leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations. There are now MFN deals with each of those leading pharmaceutical manufacturers. On September 30, 2025, President Trump announced the first agreement, with the drug manufacturer Pfizer, to bring MFN prices to American patients. On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines. On December 19, 2025, President Trump announced nine new agreements with major pharmaceutical companies. On February 5, 2026, President Trump launched TrumpRx.gov , where patients can access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the MFN price. As of today, August 31, the Administration now has agreements with Pfizer, Astra Zeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, Regeneron, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. President Trump is calling on Congress to enact the Great Healthcare Plan , a comprehensive plan to lower drug prices, lower insurance premiums, hold big insurance companies accountable, and maximize price transparency. Source: Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White House
MORE POSTS